A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Trial Profile

A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs JNJ 48816274 (Primary)
  • Indications Insomnia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 6 Oct 2017 to 30 Nov 2017.
    • 22 Sep 2017 Planned primary completion date changed from 6 Oct 2017 to 30 Nov 2017.
    • 10 Jul 2017 Planned End Date changed from 31 Aug 2017 to 6 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top